Preparation and Characterization of IL-22 mRNA-Loaded Lipid Nanoparticles
Zahra Alghoul,
Junsik Sung,
Kenji Wu,
Gianfranco Alpini,
Shannon Glaser,
Chunhua Yang,
Didier Merlin
Affiliations
Zahra Alghoul
Institute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USADepartment of Chemistry, Georgia State University, Atlanta, GA, USA
Junsik Sung
Institute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA
Kenji Wu
Institute for Biomedical ScienceInstitute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, USA, United States
Gianfranco Alpini
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, 46220, USAResearch, Richard L. Roudebush VA Medical Center, Indianapolis, IN, 46202, USA
Shannon Glaser
Department of Medical Physiology, Texas A&M University School of Medicine, Bryan, TX, 77807, USA
Chunhua Yang
Institute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USAAtlanta Veterans Affairs Medical Center, Decatur, GA, USA
Didier Merlin
Institute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USAAtlanta Veterans Affairs Medical Center, Decatur, GA, USA
Interleukin-22 (IL-22) has been demonstrated as a critical regulator of epithelial homeostasis and repair; it showed an anti-inflammatory effect against ulcerative colitis. Local microinjection of IL-22 cDNA vector has been shown to be effective in treating ulcerative colitis in mouse models. However, microinjection comes with multiple technical challenges for routine colon-targeted drug delivery. In contrast, oral administration can get around these challenges and provide comparable efficacy. We showed in previous studies that oral administration of new lipid nanoparticles (nLNP)-encapsulated IL-22 mRNA targets the colon region and efficiently ameliorates colitis. This protocol describes the details of preparing and characterizing the nLNP-encapsulated IL-22 mRNA using three major lipids that mimic the natural ginger-derived nanoparticles. It provides an nLNP platform that can be used to orally deliver other types of nucleic acids to the colon.
